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Providing thromboprophylaxis to patients who
have sustained multiple traumatic injuries can present
a significant challenge. Lower extremity injury may
preclude the use of pneumatic compression devices,
and concealed bleeding or the need for operations
may present a contraindication to anticoagulation.
The efficacy of serial venous duplex screening may be
limited because of lower extremity edema, body
habitus, or complex dressings. Although these inter-
ventions are limited, patients with trauma are at sig-
nificant risk for thromboembolism with its associated
morbidity, mortality, and cost. The risk has been
reported as 32% to 58%, depending on the extent of
injury and the use of prophylaxis.1,2 Many trauma
surgeons have opted for the prophylactic use of vena
caval filters to manage this risk. Although filters do
not prevent deep venous thrombosis (DVT), they do
prevent fatal pulmonary embolism (PE).
In a previous publication,3 we reported a cohort
study in which a group of 80 patients without pro-
phylactic filters was compared with a subsequent
group of 40 patients who had prophylactic filters.
We found a significant difference in the incidence of
PE (1 vs 14; P = .02); PE-related mortality (0% vs
8%) and overall mortality (2 vs 13) were also
reduced. Our results are similar to those reported by
Rogers et al,4 Wilson et al,5 Langan et al,6 and
Khansarinia et al.7 The successful use of filters in
patients with trauma without thromboembolism as
an extension of the indications is well documented,
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but it has raised questions regarding outcomes in
these younger patients, for whom the risk of throm-
boembolism may be time limited. It has even led
some to suggest that these patients are candidates
for temporary or retrievable filters.8 The purpose of
this study was to compare the outcomes for patients
with trauma with prophylactic filters with those for
patients who had filters placed after DVT or throm-
boembolic events to determine whether such con-
cerns are justified.
METHODS
The Michigan Filter Registry contains prospec-
tively collected data for 2188 patients who have
received vena caval filters at the University of
Michigan. We selected a subset of patients who had
trauma as the primary or secondary diagnosis
between January 1990 and August 1999 and strati-
fied the members of this group with respect to
whether they had DVT or PE before filter place-
ment. These data sets were then reviewed through
use of the joint International Society of
Cardiovascular Surgery/Society of Cardiovascular
and Interventional Radiology reporting standards
for vena caval filters.9,10 Outcomes were compared
on the basis of these standards, and the results were
analyzed through use of SAS software (version 6.12,
SAS Institute, Cary, NC). Outcomes for patients
enrolled before 1997 were previously presented but
not published.11 This report extends follow-up for
those patients and includes 137 subsequent cases.
Efforts to obtain information included routine
annual clinical evaluations, abdominal radiographs,
and ultrasound scanning examinations of the lower
extremities and inferior vena cava (IVC). For those
without routine follow-up, data from computed
tomography (CT) scans and plain or angiographic
films were reviewed for evidence of mechanical
problems with the filter, vena caval occlusion, or pul-
monary embolism. A patient was categorized as hav-
ing PE if (1) there was a ventilation-perfusion scan
with a high probability score or a positive pulmonary
angiogram or spiral computed tomogram, (2) there
was a positive autopsy finding, or (3) the patient
reported a PE at follow-up. Caval occlusion was
defined as the inability to image the IVC on CT scan
or on a cavogram or during an interpretable duplex
scan when the Doppler scanning signal was missing.
Filter migration was defined as a vertical change in
location of more than 20 mm. A change in the filter
Table I. Demographics of patients with trauma receiving vena caval filters
Prophylactic Therapeutic
No. of patients 249 136
Sex (male:female) 154:95 81:55
Mean age (y) 43 (range, 14-88) 46 (range, 11-93)
Mortality 15.6% 22%
Follow-up 79% 71%
Documented DVT or PE at placement 0 123 (90%)
Mean injury severity score 25 (4-75) 20 (4-54)*
Hospital length of stay (days) 33.8 (1-181) 38.5 (6-118)
ICU length of stay (days) 14.1 (1-150) 15.4 (2-93)
*P < .05.
Comparison between therapeutic and prophylactic indications for filter insertion in trauma patients,
1990-1996. Prophylactic indication became standard practice in 1993.
JOURNAL OF VASCULAR SURGERY
492 Greenfield et al September 2000
base diameter of more than 7 mm was considered
evidence of thrombotic contraction or penetration.
These measures were defined by a consensus panel
of radiologists and vascular surgeons (Boston, Mass,
1995) and accepted by the US Food and Drug
Administration (FDA) as part of the 510K submis-
sion for the percutaneous stainless steel Greenfield
filter (PSGF) in 1996.
RESULTS
Trauma was the primary or secondary diagnosis
for 385 (17.6%) of 2188 patients with filters placed
at the University of Michigan. In 249 (65%) of these
cases, there was no DVT or PE at the time of filter
placement, and the filters were considered prophy-
lactic. In this subset, designated group P, there were
235 male patients and 150 female patients. The
mean age was 45 years (range, 11-93 years), and the
average follow-up time was 42 months (range, 0-
172 months). As of August 1999, 286 of these
patients were alive, 30 had been lost to follow-up,
and 69 (18%) were dead, 13 with autopsy. Follow-
up data, obtained prospectively, came from routine
examinations, duplex ultrasound scanning examina-
tions (234 cases), plain radiographs (283 cases), and
CT scans (50 cases). We stratified the data according
to the absence or presence of thromboembolism
(prophylactic vs therapeutic); summarized demo-
graphic, placement and follow-up outcomes are pre-
sented in Tables I through III.
Between 1992 and 1999, the number of therapeu-
tic filters representing the rate of recognized disease
remained relatively stable, while the number of pro-
phylactic filters increased steadily (Figure). These
placements occurred in patients at risk for throm-
boembolism in whom the disease likely would have
remained asymptomatic or who would have suffered
massive or fatal PE. Criteria for filter placement,
detailed elsewhere,3 included the following: age, more
than 55 years; injury severity score, more than 15;
abbreviated injury score, more than 2; and multiple
lower extremity or pelvic fractures, spinal trauma, or
subclavian vein cannulation. In group P, 61 patients
(24%) received prophylaxis for DVT at the time of fil-
ter placement; the prophylactic treatments included
heparin, antiembolic stockings, and pneumatic com-
pression devices. However, 87% of the patients in this
group went on to receive prophylaxis at a later time.
The delay was due to orthopedic surgery in 60% of
cases and other types of procedures in 33%. No clini-
cal advantage was seen with respect to PE or caval
patency (P > .05), but there was a significant difference
in the number of patients who reported clinically evi-
dent lower extremity edema, which occurred in six of
those with prophylaxis and 32 of those without (P =
.03). Males outnumbered females in both groups. The
prophylactic patients were 3 years younger, on aver-
age, and had shorter follow-up times. However, this is
partially due to the 10 years of accrual advantage in the
therapeutic population (group T).
Table II. Filter insertion results in patients with trauma
Prophylactic Therapeutic
Radiology placement 100% 97%
Percutaneous method 100% 100%
Type of filter
PSGF 131 (52.7%) 49 (36%)
Titanium 118 (47.3%) 87 (64%)
Location
Infrarenal 243 (97.6%) 119 (94.9%)
Suprarenal 6 (2.4%) 4 (2.9%)
Route
Right femoral 205 (82%) 103 (75%)
Left femoral 35 (14%) 18 (13%)
Right jugular 4 (1.6%) 16 (11.7%)*
Other 5 (2%) 9 (6.6%)
Problems
Misplacement 0 1 (0.7%)
Incomplete opening 1 (0.4%) 0
Asymmetry 9 (3.6%) 6 (4.4%)
Tilt 1 (0.4%) 1 (0.7%)
Morbidity
Bleeding† 2 (0.8%) 1 (0.7%)
Hematoma† 1 (0.4%) 1 (0.85)
*P < .005.
†None required intervention.
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The patients in group P appeared to be more
acutely injured at admission, as indicated by a mean
injury severity score of 24 (range, 4-75); this com-
pared with a mean injury severity score of 20 (range,
4-54) for the patients in group T (P < .05). However,
the therapeutic group had longer intensive care unit
(ICU) and overall lengths of stay, suggesting a more
serious condition. Thromboembolism was objective-
ly documented in 90% of the patients in the thera-
peutic group. The remaining 10% had diagnoses
based on histories of DVT/PE or clinical signs and
symptoms without objective testing. The two groups
were equivalent with respect to the number who had
follow-up (Table I).
Filter placement was performed almost exclusive-
ly by radiologists who used a percutaneous tech-
nique. Ten filters were placed above the renal veins,
nine in females anticipating pregnancy and one in a
male, for unknown reasons. The groups differed
with respect to the ratio of PSGFs to titanium filters;
this difference is due to the later introduction of the
PSGF (in 1995). Most of the devices in both groups
were placed in the vena cava infrarenal from a right-
sided femoral vein access. Adverse placement events
were rare in both groups, as was procedural morbid-
ity (Table II). A higher percentage of insertions in
which the jugular vein was used for access was noted
for patients with documented DVT (11.7%) than for
those without (1.6%; P < .005). Despite the radiol-
ogists’ preference for the right femoral vein, they
tended to use the jugular vein when a large throm-
bus was present at this site.
Long-term outcomes are available for 79% of the
prophylactic patients (group P) and 71% of the ther-
apeutic patients (group T). Most of the data (75%
and 89%, respectively) were obtained from routine
examinations, which included physical observation,
venous duplex scanning examinations of the IVC
and lower extremities, and abdominal radiographs.
In addition, autopsy reports and results of CT scans
of the abdomen obtained for other reasons were
included. The mean follow-up time was 2.4 years for
group P and 1.9 years for group T. Patients in the
prophylactic group were anticoagulated less often
(15% vs 38%) and used support stockings less often
(3.5% vs 25%; P < .005), but had a comparable inci-
dence of venous ulceration (3.5% vs 2.3%; P > .05).
Ulcers developed early in the clinical course of 5
patients in the prophylactic group, but 4 of these 5
had healed by the time of the last follow-up.
The rate of insertion site thrombosis discovered
during routine follow-up duplex scanning studies
was slightly lower in group P (2%) than in group T
(6%; P = .28). Thirty-nine patients (15.6%) in the
Table III. Long-term outcomes of filter placement in patients with trauma
Prophylactic Therapeutic
197 (79%)* 96 (71%)
Outcome
Anticoagulation after discharge 22 (15%) 33 (38%)
Complication w/anticoagulation 1 (4.5%) 0 (0%)
Support stockings 5 (3.5%) 22 (25%)†
Venous ulcer 5 (3.5%) 2 (2.3%)
Ulcer healed 4/5 (80%) —
Lower extremity edema 38 (25%) 37 (43%)†
Insertion site thrombosis 3 (2%) 5 (5.8%)
New DVT‡ 16 (10.8%) 10 (8.6%)
Caval penetration 0 (0%) 2 (2.3%)
Migration ≥ 20 mm 2 (1.4%) 4 (4.6%)
Change in filter diameter ≥ 7 mm 2 (1.4%) 5 (5.8%)
Tilt ≥ 15° 3 (2%) 2 (2.3%)
Filter occlusion 5 (3.5%) 2 (2.3%)
Occlusion at last FU 2 (1.4%) 0 (0%)
New PE 3 (1.5%) 2 (2%)
Method of follow-up
Routine 148 (75%) 86 (89%)
Autopsy 6 (3%) 3 (3%)
CT/cavogram 48 (25%)§ 2 (2%)
No. of observations per patient 1.8 2.6
Time from placement to last follow-up (y) 2.4 1.9
*Based on patients who underwent routine follow-up.
†P < .005.
‡Among those who had duplex scan screening.
§Total adds up to more than 100% because some patients had more than one method.
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prophylaxis group developed DVT after filter place-
ment. At follow-up, there were 16 patients (10.8%)
in group P and 10 patients (8.6%) in group T (P >
.05) with new DVT. These were in addition to the 23
patients in group P—in comparison with one patient
in group T—who had symptomatic DVT during
hospitalization. Mechanical changes such as migra-
tion, change in filter base diameter, and tilt were rare
and both clinically and statistically insignificant. Vena
caval patency was 96.5% in the prophylaxis group;
this improved to 98.6% by the time of last follow-up,
according to evidence from 48 CT scans and 148
duplex scanning studies. Comparable rates in the
therapeutic group were 98% and 100%, according to
evidence from two CT scans and 86 ultrasound scan-
ning studies. There were 5 PEs after filter placement;
3 of these were in the prophylactic group (1.5%) and
2 were in the therapeutic group (2%).
DISCUSSION
Endothelial damage, hypercoagulability, and
prolonged immobility place multiply injured
patients at high risk for thromboembolism, inas-
much as they have fulfilled all of Virchow’s triad of
causative factors. This condition often develops
within the first several hours after injury, with DVT
or PE noted clinically within the first 72 hours.
Failure to address the need for prophylaxis in the ini-
tial injury phase may result in unnecessary morbidi-
ty and mortality. Waiting until the patient has had an
operation or for a decrease in the risk of bleeding to
initiate heparin prophylaxis is inappropriate. In addi-
tion, up to 35% of these patients have orthopedic
conditions that preclude the use of compression
devices. Placement of filters in patients at very high
risk of thromboembolism is an appropriate interven-
tion; it was adopted at our institution in 1993.
Several investigators have reported their experience
with prophylactic filters in trauma patients.6,7,12-15 In
these series, prophylactic filter placement was shown
to be a safe and effective method of reducing 
morbidity and mortality from pulmonary embolism
(Table IV). The overall mortality rate from PE in
these reports exceeded 50%—a fact that provides fur-
ther evidence of the need for protection in this gener-
ally younger population. The 23% incidence of DVT
after filter placement highlights the importance of
providing DVT prophylaxis whenever possible to
prevent both DVT and the morbidity associated
with the postthrombotic syndrome.
In a survey of trauma centers by Quirke et al,16
it was noted that filters were placed by radiologists at
81% of centers with trauma cases and that vascular
surgeons were responsible for such placement in
34% of the others. Many of these patients are too ill
to be moved to the radiology suite; placement dur-
ing the critical first hours is thus delayed. Nunn et
al,17 Sing et al,18 and Rose et al19 have reported suc-
cess in placing filters at the bedsides of patients with
trauma too unstable for transfer. Rose et al19 and
Sing et al18 have described a traditional fluoroscop-
ic-guided method in which portable radiographic
equipment was used with ultrasound scanning to
confirm caval and insertion site patency; all of these
procedures were successful. Vascular surgeons used
external, ultrasound-guided placement successfully
in 49 of the 55 cases in which it was attempted. The
six failures were due to inability to locate the renal
vein or a large caval diameter. The use of intravascu-
lar ultrasound scanning may eliminate this problem.
Not only did ultrasound-guided filter placement
improve the safety of such prophylaxis by keeping
patients in the ICU; it also reduced charges by
$1481 per patient in comparison with use of the
radiology suite and by $2432 in comparison with
use of the operating room.19
Although the right femoral vein has been the
preferred access for filter insertion, the right jugular
vein has the advantage of avoiding carrier passage
near or through existing DVT. This approach was
used significantly more often in the therapeutic
group in our series and has the additional advantage
of a reduced rate of insertion site thrombosis. Tilting
or asymmetry of the filter legs was seen in 5% or
Table IV. Thromboembolic events after prophylactic filter placement in studies since 1994
N Follow-up PE Occlusion New DVT
Lanagun, 1999 187 75 1 0 24
Khansarinia, 1995 108 – 0 – –
Zolfaghari, 1995 45 – 0 – –
Patton, 1996 110 45 0 0 14
Rodriguez, 1996 40 40 1 4 6
Rogers, 1998 132 47 3 1 10
Current study 249 196 3 3 39
Totals 871 403 8 (1.9%) 8 (1.9%) 93 (23%)
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fewer of the patients in both groups and had no cor-
relation with recurrent PE. Differences between the
groups were seen in the increased edema and use of
support stockings in the therapeutic patients. In
addition to more extensive DVT in these patients,
there may have been more extensive lower extremi-
ty injuries, although this was not assessed or docu-
mented. Interestingly, the incidence of venous ulcer
was essentially the same in both groups, at 2% to
3.5%; however, it is well known that this complica-
tion is likely to increase with the passage of time in
the presence of chronic venous insufficiency. The
long-term stability of the filter has been document-
ed in previous reports,20-22 and the absence of late
filter-related complications provides reassurance
with respect to its use in younger patients.
From our own experience and that of others, it is
evident that there is a role for prophylactic IVC fil-
ter placement in patients with trauma. It is also clear
that taking steps to reduce morbidity, such as pro-
viding continued DVT prophylaxis and improving
procedural safety with bedside placements, is impor-
tant. The final and perhaps most important question
that remains is how to select for filter placement only
the 25% of patients who will go on to have throm-
boembolism. More focused risk stratification will
dramatically reduce the number of patients who
need to be treated and will improve the cost-
effectiveness of this approach.
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Dr Eugene M. Langan III (Greenville, SC). The authors
from the University of Michigan again address the important
question of placing inferior vena cava filters prophylactically
in the multi-injured trauma patient. This current study
expands on their previous report by adding an additional
137 patients. They utilize the Michigan filter registry of over
2000 patients to report the largest series to date of prophy-
lactic filters in 235 patients, 196 with follow-up data.
As an advocate for this procedural indication for IVC
filters, I think the authors should be congratulated for their
extremely comprehensive follow-up data. Follow-up
included physical exam, abdominal radiographs, ultrasound
studies of the vena cava and lower extremities, and CT
scans and autopsies when available. They also went to
extensive measures to document filter migration. This is no
small task in a patient population that, in our experience,
can be extremely difficult to maintain follow-up data on. 
On review of this manuscript I have four questions.
First, Dr Greenfield, you state that for the inferior vena
cava filter placement to have its maximum pulmonary
embolism prophylaxis, it needs to be placed in the first 72
hours, yet you do not relate your IVC filter insertion day.
Therefore, I would like to know your average day after
trauma that the filters were placed.
My second question involves the six suprarenal filters.
If none of the patients in the prophylactic group had a
preinsertion deep venous thrombosis or pulmonary
embolism, why were suprarenal filters placed?
The third question involves your discussion of the use
of intravascular ultrasound. I was very interested in this
technique and would be interested in your description of
the use of intravascular ultrasound with and without fluo-
roscopic assistance.
My final question is about your registry, which I will
admit my jealousy of. If the inferior vena cava filters are
placed by radiologists and patient management and fol-
low-up are by trauma surgeons, how do you maintain your
registry data?
I would like to thank the association for the privilege
of reviewing this very interesting manuscript, which I truly
enjoyed, and Dr Greenfield and associates for getting me
this manuscript in a timely fashion. Thank you.
Dr Lazar J. Greenfield. Thanks very much for those
insightful comments. First, on the time of insertion, at the
time that the protocol was established in 1995 by Dr Jorge
Rodriguez, who was in charge of the trauma service, it
called for filter insertion within 24 hours. Patient logistics
in many of the situations would obviously extend this to
48 hours, but most of the filters were inserted within the
48-hour period that we would feel important for maximal
protection.
On the question of suprarenal insertion, we elected to
put filters suprarenal when we were dealing with younger,
fertile females, who would anticipate future pregnancy. We
have always felt that there is good reason to put the filter
above the level that might be compressed by the gravid
uterus. Even though we have no documented evidence of
problems in that regard, I do believe that is the safest and
actually most effective placement because it also covers the
drainage from the pelvis. 
As far as the IVUS is concerned, all of our own work
has been experimental. John Matsumara has reported clin-
ical experience with this, and I think it offers a great
advantage in terms of being able to insert the device at the
bedside. What we have observed is that it is very easy to
identify branches and the renal vein at the time of inser-
tion. What is not standardized is whether punctures are
required in both sides in order to image the device while
you are inserting it and to confirm its precise location. 
As far as follow-up is concerned, we did not trust the
trauma service for follow-up. All of the follow-ups were
scheduled through vascular surgery. That enabled us to
track the patients through all of the assessments that
occurred in the vascular laboratory, and we obtained our
data by rigorous efforts to obtain the information at the
time of insertion and then to persuade the patients that it
was in their best interest to return.
Dr James W. Dennis (Jacksonville, Fla). I commend
you again, Dr Greenfield, for your long-term follow-up
efforts. I have a comment and a question.
The first comment is that I hope that this, as you men-
tioned in your manuscript, is another nail in the coffin of
this concept that we need a temporary filter. I think that is
based on the assumption that these permanent filters have
some long-term bad side effect that has never been
proven, and I think that this paper continues to illustrate
the fact that is just an assumption.
Secondly, other papers have shown the insertion site
thrombosis to be as high as 15%. I noted that yours is less
than that, but that has been a concern of ours. On the pro-
phylactic filters put in trauma patients, the vast majority
usually need some sort of orthopedic, neurosurgical, or
general surgical procedure, and our policy has been to put
in the filter in the operating room at the time they are hav-
ing that other procedure. This eliminates any cost advan-
tage of not doing it in the operating room. What we have
found so far is that the insertion site thrombosis rate is
essentially zero, so we have continued that policy. I was
wondering if that might be something people should also
be doing because of the 5% to 15% risk of insertion site
thrombosis. Thank you.
Dr Greenfield. I appreciate your comments and the
important work that you have done in this same population. 
Insertion venous thrombosis depends on the technique
used to compress the groin following the insertion of the
device. The radiologists with whom we work very closely
have more recently made a transition to avoiding prolonged
compression at the groin and simply relying on the patients’
ability to handle that small puncture. That has dramatically
reduced the incidence of venous thrombosis. 
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As far as the temporary filter is concerned, there is still
a lot of anxiety among trauma surgeons and other clini-
cians about what it means to a young patient to have a fil-
ter for life. We think, on the basis of more than 25 years’
follow-up, that it is an innocuous event. There will always
be that concern and that is why it is important for us to
continue to collect the data.
Dr Thomas Naslund (Nashville, Tenn). I appreciate
your report as well and would like to repeat what others
have said. I am stunned with the ability you have had with
follow-up in a very difficult patient population group to
find after performing procedures.
We have been performing prophylactic filters at the
bedside with duplex ultrasound over the last 5 years and
now have an experience of about 250 such filters placed. I
wondered what your experience was with surface ultra-
sound in the deployment of filters. We have advocated it
as the most cost-effective method, and our experience
would suggest that it is feasible in 90% or better of these
trauma patients. There is obviously a learning curve, but
we have been very satisfied with that particular procedure.
I have a second question as well. Now that you have
shown some of the safety and benefits to prophylactic fil-
ter placement in the trauma patient, there are other inten-
sive care patients where now the same question is being
raised, particularly in the medical intensive care unit. I
wonder if you have any ideas of other patient populations
that might benefit from a similar approach.
Dr Greenfield. Thanks very much, Tom. I congratulate
you on the pioneering work you have done with bedside
scanners, which have a considerable advantage. My only
concern is the patient who is difficult to image, but your
experience would suggest that 90% of the patients can be
imaged in a satisfactory manner. That allows you to do a
single puncture for the insertion of the device.
Incidentally, there is increasing interest in using the
jugular approach because ultrasound allows much more
accurate identification of the jugular vein and subsequent
placement through that access.
As far as the prophylactic indication is concerned, we
have seen a dramatic increase across the board, not just in
trauma patients. I think in situations that are borderline,
many clinicians who are hesitant to anticoagulate older
female patients are choosing filter insertion. I do not know
whether it is good or bad. We have always advocated the
use of anticoagulation because it does decrease the long-
term morbidity from venous thrombosis, but this is a
changing scene. 
Dr Thomas Schwarcz (Lexington, Ky). Dr Greenfield, I
am very intrigued by this tremendous increase in prophy-
lactic placement of these filters. We have a very active trau-
ma service, and they are very aggressive about treating the
high-risk trauma patients with enoxaparin as soon as they
enter or can tolerate that treatment. We have found a rela-
tively low incidence of DVT. I was interested in your per-
spective: do you think or have you seen that enoxaparin
treatment has lowered the rate of prophylactic filter place-
ment, or do you think it should have an effect in the future?
Dr Greenfield. I think that is an important addition to
our armamentarium, but it remains to be seen whether it
will be adequate protection for the highest risk popula-
tion. We need to refine the selection of those patients
whose risk assessment leads them to the category least
likely to be protected by low molecular weight heparin
and more likely to require the filter. Your work and oth-
ers’ will be important in that regard.
